Stephen Schoenberger, Ph.D.

My translational cancer research draws on over 20 years of activity in fundamental T cell biology to develop new approaches for precision immunotherapy of cancer targeting a subset of tumor-specific expressed mutations known as neoantigens. Our approach combines genomic sequencing, bioinformatics, and functional testing of immune responses within individual patients to identify targets for personalized treatment through vaccination and adoptive cellular therapy.